#esmo26
🔬 Left ureter transposition during robotic cystectomy. How do you safely navigate between the sigmoid mesentery, hypogastric plexus, and iliac vessels? 🎥 Watch more surgical tutorials on YouTube 👇 While #ESMO26 focuses on optimizing perioperative systemic therapy, let's not forget to optimize surgical technique too! ERUS Robotic Urology
Dries Develtere - Surgical Vision14,086 Aufrufe • vor 22 Tagen
![An OncoAlert #Podium2Screen from the #ESMO26 Presidential Session Presented by our OncoAlert 🚨faculty Tom Powles Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial Jeremy Teoh Camillo Porta 🔬 Phase 3 VOLGA trial (n=695) Evaluated perioperative durvalumab (D) ± tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) versus control (radical cystectomy [RC], followed by observation or approved adjuvant therapy) in cisplatin-ineligible muscle-invasive bladder cancer (MIBC). Just PUBLISHED in NEJM Interim analysis; median event-free survival (EFS) follow-up: 22.9 months. ➡️ D + EV: EFS HR 0.51 (95% CI, 0.38–0.67); OS HR 0.58 (95% CI, 0.40–0.83) ➡️ D + T + EV: EFS HR 0.61 (95% CI, 0.47–0.80); OS did not meet statistical significance ➡️ Pathological complete response (pCR): 45% with D + EV vs 10% with control ➡️ Grade 3/4 treatment-related adverse events (TRAEs): 30% with D + EV vs 42% with control ✅ Both primary EFS endpoints were met. Perioperative durvalumab plus 3 cycles of neoadjuvant EV also significantly improved OS. 🎙️ Presenter: Thomas Powles 👥 Investigators: Alexandra Drakaki · Jeremy Teoh · Enrique Grande · Mario Fontes-Sousa · Camillo Porta · Esther Wu · Erik Goluboff · Svetlana Ho · Stephan Hois · Ashok Gupta · James Catto Toni Choueiri, MD Tom Powles Andrea Apolo, M.D. Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO silke gillessen aurelius omlin Brian Rini, MD Petros Grivas Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) Axel S. Merseburger Daniel Heng Hans Hammers Sara Coca Membribes Andrea Necchi, MD, FASCO Amanda Nizam, MD Enrique Grande Dra. María Natalia Gandur Quiroga Laurence Albiges Daniel Castellano Declan Murphy Sean McBride Shilpa Gupta, MD, FASCO Rana McKay, MD, FASCO Simon C Yüksel Ürün Ravindran Kanesvaran David Braun Eleni Efstathiou Miguel Zugman, MD Cristiane D Bergerot, PhD, FASCO Niklas Klümper Markus Eckstein](https://image.24vids.com/tw-2114016348481245279/amplify_video_thumb/2114015085215485952/img/qHVCzp7jHGii-LFH.jpg)
An OncoAlert #Podium2Screen from the #ESMO26 Presidential Session Presented by our OncoAlert 🚨faculty Tom Powles Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial Jeremy Teoh Camillo Porta 🔬 Phase 3 VOLGA trial (n=695) Evaluated perioperative durvalumab (D) ± tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) versus control (radical cystectomy [RC], followed by observation or approved adjuvant therapy) in cisplatin-ineligible muscle-invasive bladder cancer (MIBC). Just PUBLISHED in NEJM Interim analysis; median event-free survival (EFS) follow-up: 22.9 months. ➡️ D + EV: EFS HR 0.51 (95% CI, 0.38–0.67); OS HR 0.58 (95% CI, 0.40–0.83) ➡️ D + T + EV: EFS HR 0.61 (95% CI, 0.47–0.80); OS did not meet statistical significance ➡️ Pathological complete response (pCR): 45% with D + EV vs 10% with control ➡️ Grade 3/4 treatment-related adverse events (TRAEs): 30% with D + EV vs 42% with control ✅ Both primary EFS endpoints were met. Perioperative durvalumab plus 3 cycles of neoadjuvant EV also significantly improved OS. 🎙️ Presenter: Thomas Powles 👥 Investigators: Alexandra Drakaki · Jeremy Teoh · Enrique Grande · Mario Fontes-Sousa · Camillo Porta · Esther Wu · Erik Goluboff · Svetlana Ho · Stephan Hois · Ashok Gupta · James Catto Toni Choueiri, MD Tom Powles Andrea Apolo, M.D. Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO silke gillessen aurelius omlin Brian Rini, MD Petros Grivas Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) Axel S. Merseburger Daniel Heng Hans Hammers Sara Coca Membribes Andrea Necchi, MD, FASCO Amanda Nizam, MD Enrique Grande Dra. María Natalia Gandur Quiroga Laurence Albiges Daniel Castellano Declan Murphy Sean McBride Shilpa Gupta, MD, FASCO Rana McKay, MD, FASCO Simon C Yüksel Ürün Ravindran Kanesvaran David Braun Eleni Efstathiou Miguel Zugman, MD Cristiane D Bergerot, PhD, FASCO Niklas Klümper Markus Eckstein
OncoAlert10,374 Aufrufe • vor 21 Tagen
Keine weiteren Inhalte verfügbar